Testosterone replacement and prostate cancer

Ranjith Ramasamy, Erik S. Fisher, Peter N. Schlegel

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

This article is intended as a review of the available clinical data outlining the risks and benefits of testosterone (androgen) replacement therapy, specifically addressing the issue of the relationship between exogenous androgen administration and prostate cancer risk. There is controversy over whether androgen replacement is a risk factor for incident prostate cancer. Our review of current clinical information revealed that to date, no study or review has definitively shown that androgen replacement therapy is an independent risk factor for development of prostate cancer. Androgen administration seems to be beneficial in decreasing fatal cardiovascular events, body fat mass, and insulin resistance. Overall, the current clinical data seems to suggest that androgen replacement is an appropriate therapeutic option for men with symptomatic hypogonadism provided that patients continue to receive regular prostate screenings.

Original languageEnglish (US)
Pages (from-to)123-128
Number of pages6
JournalIndian Journal of Urology
Volume28
Issue number2
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

    Fingerprint

Keywords

  • Androgen replacement
  • hypogonadism
  • prostate

ASJC Scopus subject areas

  • Urology

Cite this